|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61P 35/00 | (2006.01) |
| A61K 39/00 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| C07K 16/28 | (2006.01) |
| (11) | Number of the document | 4058148 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20729951.2 |
| Date of filing the European patent application | 2020-05-08 | |
| (97) | Date of publication of the European application | 2022-09-21 |
| (45) | Date of publication and mention of the grant of the patent | 2024-03-13 |
| (46) | Date of publication of the claims translation | 2024-05-27 |
| (86) | Number | PCT/EP2020/062876 |
| Date | 2020-05-08 |
| (87) | Number | WO 2021/094000 |
| Date | 2021-05-20 |
| (30) | Number | Date | Country code |
| 19208417 | 2019-11-11 | EP |
| (72) |
STIEGLMAIER, Julia , DE
HUBER, Birgit , DE
MINELLA, Alexander , US
UPRETI, Vijay , US
|
| (73) |
Amgen Research (Munich) GmbH ,
Staffelseestrasse 2, 81477 München,
DE
Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320-1799, US |
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Agentų prieš BCMA dozavimo režimas |
| DOSING REGIMEN FOR ANTI-BCMA AGENTS |
| Payment date | Validity (years) | Amount | |
| 2025-04-23 | 6 | 139.00 EUR |
| 2026-05-08 |